Every client with graying hair eventually asks the same question. Can it come back? For a long time, the honest answer was no. Gray hair was understood as a consequence of melanocyte exhaustion. Once the pigment-producing cells were gone, they were gone, and there was nothing to do about it except dye it or accept it.
The science is now more complicated than that. Not in a "take this supplement and watch it reverse" way, but in a genuinely mechanistic, this-is-how-biology-actually-works way. A 2023 Nature study out of NYU Langone changed how researchers think about graying entirely. Since then, studies in 2024 and 2025 have been testing specific interventions grounded in that new understanding: a natural compound from vegetables, plant-derived melanogenesis stimulators, and early exosome therapy trials.
Your clients are going to ask about this. The supplement brands are already running with the headlines. You need to understand what the research says before you can give anyone a straight answer.
Why Hair Goes Gray: A Quick Grounding
Hair gets its color from melanin, produced by melanocytes in the hair matrix at the base of the follicle bulb. These melanocytes transfer melanin granules into the cortical cells forming the hair shaft. Eumelanin gives you brown to black shades. Pheomelanin gives yellow to red. The ratio determines the natural color you were born with.
Melanocytes don't have an indefinite lifespan. They're continuously replenished from a reservoir of melanocyte stem cells (McSCs) sitting in a specific region of the follicle called the bulge. Each anagen phase, McSCs are supposed to migrate downward into the hair germ, receive signals to differentiate, mature into active melanocytes, and get to work pigmenting the new shaft. The key word there is "supposed to."
For years, the dominant explanation for graying was straightforward depletion: the McSC pool empties out with age, no new melanocytes form, and the follicle starts producing colorless hair. That explanation is partially correct. But a landmark study published in 2023 showed it's not the whole story, and the part it was missing changes everything.
The "Stuck Stem Cell" Discovery
The NYU team, led by Dr. Mayumi Ito, used live imaging and single-cell RNA sequencing to track exactly what McSCs do during normal hair cycling. What they found challenged the prevailing model entirely.
McSCs are not static. Under healthy conditions, they're constantly in motion, moving back and forth between the bulge (where they rest in a primitive stem cell state) and the hair germ below it (where WNT protein signals prompt them to differentiate into pigment-producing melanocytes). This cycling between states, this back-and-forth, is what keeps the pigment system running. The researchers called it dedifferentiation: the cells don't move in one direction from stem to mature. They toggle.
The problem starts when that movement breaks down. As hair cycles through aging, either naturally or in the study's experimental model via repeated plucking and regrowth, a growing percentage of McSCs get lodged in the bulge. Stuck there. They never receive the WNT signals that would activate them. They don't differentiate. They don't produce pigment. The hair grows in gray not because the cells are gone, but because they've stopped doing the job they're still physically present to do.
The McSCs that kept moving, the ones that continued cycling between bulge and hair germ, retained their ability to regenerate and produce pigment across the entire two-year study period. The ones that stopped moving stopped contributing. "It is the loss of chameleon-like function in melanocyte stem cells that may be responsible for graying and loss of hair color," said Dr. Ito.
Previous research framed gray hair as a problem of cell death and permanent depletion. This study reframes it as a problem of cellular immobility, at least in the early and middle stages. Cells that are stuck are still alive. A stuck cell is, in theory, a cell that could potentially be moved. That is a fundamentally different therapeutic target than a cell that no longer exists. Graying only becomes truly irreversible once the McSC pool itself is exhausted, which happens later in the process. There may be a window.
The Role of WNT Signaling
WNT proteins are the critical activating signal that McSCs need to transition from their resting, undifferentiated state in the bulge to the transit-amplifying state in the hair germ where they eventually mature. The NYU team had previously established that WNT signaling in the bulge is dramatically lower than in the hair germ, which is exactly why bulge-residing cells stay in a primitive, non-pigmenting state under normal conditions.
When McSCs get stuck in the bulge, they stay in a low-WNT environment indefinitely. Without that activation signal, they never differentiate. The irony is that WNT exposure has to be precisely calibrated: too much triggers premature differentiation and eventual stem cell exhaustion, too little leaves them inert. This is why the "just boost WNT" answer doesn't exist. The system requires dynamic regulation, not a one-way switch.
What Dr. Ito's team proposed is that future therapies might work by restoring McSC motility, physically nudging cells out of the bulge or strengthening the signals that guide them back toward the hair germ, without disrupting the broader regulation that keeps the follicle cycling correctly. That's the therapeutic hypothesis driving current research.
Luteolin: A Natural Compound That Targets the Endothelin Pathway
Published in December 2024 by researchers at Nagoya University, this study tested three antioxidants, luteolin, hesperetin, and diosmetin, for their effects on hair graying in a specific mouse model designed to replicate the human graying process. Only luteolin worked. And it worked whether the researchers applied it topically or fed it to the mice orally.
The mechanism wasn't about killing free radicals in a generic sense. Luteolin specifically targeted the endothelin signaling pathway between keratinocyte stem cells (KSCs) and McSCs in the follicle bulge. In aging follicles, KSCs reduce their expression of endothelin ligands, and McSCs lose expression of the endothelin receptor (Ednrb). That breakdown in communication is one of the signals that leaves McSCs inactive. Luteolin suppressed the increase in p16ink4a-positive senescent cells in the bulge, cells that contribute to that KSC-McSC communication failure, and preserved endothelin receptor expression in McSCs.
Critically, luteolin had limited effects on hair cycling. It didn't change how fast hair grew or how often it shed. Its impact was specifically on pigmentation. That kind of targeted action matters for interpreting what you're actually dealing with.
Luteolin is a flavonoid found in celery, broccoli, carrots, onions, and peppers. It's already commercially available as a supplement. The Nagoya team noted that no comprehensive human safety data exists yet for luteolin in the concentrations tested, and further research is needed before clinical application. This is a promising early finding, not a treatment protocol. The gap between "works in mice" and "safe and effective in humans" is real and should not be papered over.
Plant-Derived Compounds and Melanogenesis
This 2025 review compiled evidence on plant-derived compounds that upregulate melanogenesis through different molecular mechanisms. The core target across most of these compounds is MITF, microphthalmia-associated transcription factor, the primary regulator of melanin synthesis. MITF activates downstream genes including tyrosinase (TYR), the rate-limiting enzyme in melanin production, and structural melanosome proteins.
Several plant monomers showed meaningful activity in cell and animal models:
The researchers were careful to acknowledge real limitations. Most of the data is in vitro or from animal models. Clinical validation in humans is largely absent. The specific upstream signaling mechanisms for several compounds remain poorly characterized. A systematic evaluation system for assessing clinical efficacy needs to be developed. This is promising preliminary science, but it's not a protocol for reversing gray hair in your client next week.
Exosome Therapy: Early Clinical Data
This is the most clinically proximate study in the current gray hair research landscape. Ten patients with visible gray or white hair were treated with rose stem cell-derived exosomes (RSCEs) delivered via jet-based transdermal device across six sessions.
Progressive repigmentation was documented in patients beginning at 4 weeks, with continued darkening of hair shafts observed at 12 weeks. The proposed mechanism is that exosomes, which are extracellular vesicles packed with signaling proteins and RNA, can deliver regenerative signals to dormant McSCs and surrounding follicular cells, potentially restoring the intercellular communication that gets disrupted during graying.
Ten patients is a small observational study. There's no control group. The treatment protocol varied between patients. These are important caveats. What this study does provide is a proof-of-concept: clinical repigmentation following exosome treatment is observable and documentable, and the mechanism is scientifically grounded in what we now understand about McSC biology. It's a starting point, not a finished answer.
Exosome therapies currently sit in a regulatory gray area in the United States. The FDA has issued guidance that most exosome products lack approval as biological drugs. As of 2026, exosome injections and devices are being used in aesthetic and hair medicine settings, but administration is a physician-supervised or physician-performed procedure. Trichologists should not be administering these treatments. Your role is to understand the science well enough to speak to it accurately, refer appropriately, and support clients through whatever path they're pursuing. Do not let clients conflate a topical "exosome serum" from a beauty brand with the clinical protocol studied here. They are not the same thing.
What This Means for Trichologists
The gray hair conversation has shifted. For the first time, there's a mechanistic basis for the idea that graying could be partially reversible under the right conditions. That doesn't mean it's easy, or that anything in current clinical practice reliably reverses gray at scale. But the scientific foundation now exists in a way it didn't five years ago.
Know the mechanism before the client does. When someone comes in having read a headline about luteolin or exosome therapy reversing gray hair, you should be able to explain what's actually happening at the cellular level. The McSC mobility model, the endothelin signaling axis, the MITF-tyrosinase pathway. Not to impress them with terminology, but because understanding the biology is the only way to evaluate what's plausible and what's marketing.
Distinguish between early and late-stage graying. The NYU research makes clear that gray hair becomes irreversible when the McSC pool itself depletes. That happens over time, and the timeline varies by individual. A client in their late 30s with recently graying temples is in a different biological situation than someone who has been fully gray for 15 years. Early intervention, if effective therapies emerge, will require early identification. Trichoscopy can reveal follicular activity and miniaturization but cannot currently distinguish stuck McSCs from depleted ones. That's a diagnostic gap the field is working on.
Don't overclaim for anything currently available. There is no FDA-approved treatment for gray hair reversal. Luteolin supplements are sold freely, but human efficacy and safety data is not yet established. Plant-derived melanogenesis stimulators are being studied, not prescribed. Exosome therapy for repigmentation requires physician oversight and is not standard of care. If a product is claiming to reverse gray hair based on any of this research, it's ahead of the evidence. Tell your clients that clearly.
This is an area worth following closely. The science is moving fast. The NYU team has announced plans to investigate ways to restore McSC motility in vivo. The luteolin data from Nagoya will likely generate follow-up human trials. Exosome protocols will become more standardized as the regulatory picture clarifies. In a few years, this may look very different. Staying current on the peer-reviewed literature is part of the job, and that's exactly what we're built to help you do at The Scalp Society.
The Bottom Line
Gray hair is no longer simply a story of cells dying. A landmark 2023 Nature study established that melanocyte stem cells get stuck in the follicle bulge, losing access to WNT signals that would activate them, while they remain physically present but functionally silent. That opens a theoretical window for reversal before total McSC depletion occurs. Research in 2024 and 2025 has tested specific interventions targeting this biology: luteolin via the endothelin pathway, plant-derived compounds that upregulate melanogenesis through MITF, and exosome therapy with early clinical repigmentation data in 10 patients. None of these are treatment protocols yet. All of them are real science, pointing toward a future where gray hair management looks nothing like what's currently available.